Fostamatinib disodium + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Antibody Autoimmune Hemolytic Anemia
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Trial Timeline
Apr 24, 2019 → Apr 11, 2022
NCT ID
NCT03764618About Fostamatinib disodium + Placebo
Fostamatinib disodium + Placebo is a phase 3 stage product being developed by Rigel Pharmaceuticals for Warm Antibody Autoimmune Hemolytic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03764618. Target conditions include Warm Antibody Autoimmune Hemolytic Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03764618 | Phase 3 | Completed |
| NCT02076412 | Phase 3 | Completed |
| NCT02076399 | Phase 3 | Completed |
Competing Products
12 competing products in Warm Antibody Autoimmune Hemolytic Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |